85 results about "Adenosine a" patented technology

A myocardial imaging method that is accomplished by administering one or more adenosine A_2A adenosine receptor agonist to a human undergoing myocardial imaging as well as pharmaceutical compositions comprising at least one A_2a receptor agonist, at least one liquid carrier, and at least one co-solvent.

A prophylactic and/or therapeutic agent for diseases accompanied by chronic musculoskeletal pain comprising as an active ingredient a compound having an adenosine A_2A receptor antagonistic action, for example, represented by the following formula (I) (wherein R¹, R² and R³ are the same or different, each representing a hydrogen atom, lower alkyl, lower alkenyl or lower alkynyl; R⁴ represents cycloalkyl, —(CH₂)_n—R⁵ or the following formula (II); and X¹ and X² are the same or different, each representing an oxygen atom or a sulfur atom) or a pharmaceutically acceptable salt thereof.

The present application discloses methods and compositions for increasing patient tolerability during myocardial imaging comprising the administration of doses of caffeine and one or more adenosine A_2A receptor agonists to a mammal undergoing myocardial imaging.

The invention provides methods and compositions for reducing or inhibiting bone resorption, osteoclast differentiation and stimulation and the loosening of medical prostheses by administering a compound or agent that modulates an adenosine receptor such as the adenosine A_2A receptor, in particular, an agonist of an adenosine A_2A receptor. The invention also extends to pharmaceutical compositions comprising such an agent that modulates an adenosine receptor such as an adenosine A_2A agonist and to prosthetic devices containing such an agent that modulates an adenosine receptor such as an A_2A agonist on one or more surfaces or within the prosthetic device such as, for example, suspended in the cement forming the prosthetic device.

The present invention provides a method for identifying and using partial adenosine A_2A receptor agonists that are useful as adjuncts in myocardiological perfusion imaging.

Myocardial imaging methods that are accomplished by administering doses of a pharmaceutical composition including regadenoson—an adenosine A_2A receptor agonist—to a human undergoing myocardial imaging in an amount sufficient to achieve at least a minimal increase in average coronary peak flow velocity.

This invention pertains to compounds which specifically inhibit the adenosine A₃ receptor and the use of these compounds to treat a disease associated with A₃ adenosine receptor in a subject, comprising administering to the subject a therapeutically effective amount of the compounds.

The present invention provides therapeutic agents for preventing and treating neurodegenerative diseases. These agents synergistically target both the adenosine A_2A receptor (A_2AR) and the equilibrative nucleoside transporter 1 (ENT1).

This invention pertains to compounds which specifically inhibit the adenosine A₁ and A₃ receptors and the use of these compounds to treat a disease associated with A3 adenosine receptor in a subject, comprising administering to the subject a therapeutically effective amount of the compounds.

Anxiety disorders, such as panic disorder, agoraphobia, obsessive-compulsive disorder, social phobia, post-traumatic stress disorder, generalized anxiety disorder, specific phobia, or the like, are treated by administering an effective amount of at least one adenosine A_2A receptor antagonist to a patient in need thereof, optionally in combination with an anxiolytic(s) other than the adenosine A_2A receptor antagonist.

A process for preparing adenosine from inosine by chemical synthesis method includes such steps as acetylating by excessive acetic anhydride under existence of anhydrous sodium acetate to obtain acetylinosine, chlorinating it by trichloroxyphosphate in pyridine to obtain chloro-acetylinosine, ammonolyzing in ammonia-methanol solution to obtain coarse adenosine, and refining. Its advantage is high output rate.

Disclosed are novel adenosine A₃ receptor agonists of Formula I:

• • wherein:
  • R is hydrogen or lower alkyl;
  • R¹ is optionally substituted lower alkoxy or optionally substituted cycloalkyloxy;
  • R² is hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted trialkylsilyl; and
  • R³ is hydroxymethyl or R⁴R⁵NC(Q)—;
  • in which R⁴ and R⁵ are hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl.

The present invention provides pharmaceutical compositions, which are useful for treatment of depression and the like, and which comprises a compound having an adenosine A_2A receptor antagonistic activity such as (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methyl-3,7-dihydro-1H-purine-2,6-dione or a pharmaceutically acceptable salt thereof and an antidepressant drug (for example, a tricyclic antidepressant, a tetracyclic antidepressant, a selective serotonin reuptake inhibitor, a selective noradrenalin reuptake inhibitor, a dopamine reuptake inhibitor, a serotonin-noradrenalin reuptake inhibitor, a monoamine oxidase inhibitor, a 5-HT₂ antagonist or the like), and the like.

The present invention is directed to methods of treating movement disorders by administering an effective amount of one or more adenosine A_2A receptor antagonists to a patient in need thereof. The present invention also provides methods of decreasing the adverse effects of L-DOPA in patients receiving L-DOPA therapy in the treatment of Parkinson's disease. The present invention further provides methods and compositions for treating Parkinson's disease patients with sub-clinically effective doses of L-DOPA by combining L-DOPA treatment with an effective amount of one or more adenosine A_2A receptor antagonists (i.e., L-DOPA sparing effect). The present invention further provides methods of effective treatment of Parkinson's disease by co-administering at least one adenosine A_2A receptor antagonist, L-DOPA and a dopamine agonist and/or a COMT inhibitor and/or a MAO inhibitor. The present invention further provides methods of prolonging effective treatment of Parkinson's disease by administering an adenosine A_2A receptor antagonist singly or together with a dopamine agonist, and/or a COMT inhibitor, and/or a MAO inhibitor without prior or subsequent administration of L-DOPA, delaying or removing on-set of L-DOPA motor complication.